Metastatic Pancreatic Ductal Adenocarcinoma
Conditions
Keywords
Ciprofloxacin, Gemcitabine, Nab-Paclitaxel Chemotherapy
Brief summary
This is a single-center, pilot study evaluating the addition of Ciprofloxacin (study drug) to standard-of-care gemcitabine and nab-paclitaxel chemotherapy in treatment-naïve metastatic PDAC patients. Patients who are recommended gemcitabine and nab-paclitaxel chemotherapy as a standard-of-care by their treating physician will be offered to participate in this study.
Detailed description
Oral ciprofloxacin (study drug) will be administered twice a day throughout each 28-day cycle of gemcitabine and nab-paclitaxel chemotherapy. The patient will start taking ciprofloxacin from the evening of day 1 of chemotherapy and end on the morning of day 29 of each cycle. Ciprofloxacin tablets should be taken in the morning and evening at about the same time each day. Swallow the tablet whole. Do not split, crush or chew the tablet. Ciprofloxacin can be taken with or without food With each study visit, the physician will prescribe 1-month supply of oral ciprofloxacin to be taken home and self-administered by the patient. The physician will have to indicate pancreatic cancer microbiome study on the remarks column for each cycle oral ciprofloxacin is ordered.
Interventions
DRUGCiprofloxacin
Subjects enrolled will be administered oral ciprofloxacin twice a day throughout the course of each 28-day cycle of gemcitabine and nab-paclitaxel chemotherapy.
Sponsors
National University Hospital, Singapore
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a single-center, pilot study evaluating the addition of Ciprofloxacin (study drug) to standard-of-care gemcitabine and nab-paclitaxel chemotherapy in treatment-naïve metastatic PDAC patients.
Eligibility
Sex/Gender
ALL
Age
21 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Signed informed consent. Written informed consent must be obtained prior to performing any study-related procedures. * Age ≥ 21 years * Histologically or cytologically confirmed, treatment-naïve, locally advanced or metastatic pancreatic adenocarcinoma planned to commence on gemcitabine and nab-paclitaxel chemotherapy. * Patient must have measurable disease as defined by the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1 guidelines) * Life expectancy \>3 months * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * CrCl ≥ 30 ml/min
Exclusion criteria
* Known hypersensitivity or allergy to ciprofloxacin or other quinolones * On tizanidine or theophylline and unable to stop these medication * Known QTc prolongation (QTc \>500 msec) or torsade de pointes * Presence of Clostridium difficile-associated diarrhea or colitis * Known history of myasthenia gravis * Known G6PD deficiency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Antitumor Effect - Solid Tumors | 4 years | Patients are be re-evaluated for response every 8-12 weeks (±10 days), per standard-of-care. Response and progression will be evaluated in this study using the international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in RECIST. |
Countries
Singapore
Outcome results
None listed